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Background: Epilepsy is a common health problem which carries a huge medical social psychological and
economic impact for a developing country. The aim of this hospital-based study was to get an insight into the
effectiveness and tolerability of low cost antiepileptic drugs (AEDs) in Bangladeshi people with epilepsy.
Methods: This retrospective chart review was done from hospital records in weekly Epilepsy outdoor clinic of
Department of Neurology, Dhaka Medical College Hospital (DMCH) from October 1998 to February 2013. A total of
854 epilepsy patients met the eligibility criteria (had a complete record of two years of follow up data) from
hospital database. A checklist was used to take demographics (age and gender), epilepsy treatment and adverse
event related data. At least two years of follow up data were considered for analysis.
Results: Out of 854 patients selected, majority of the patients attending outdoor clinic were >11-30 years age
group (55.2%) with a mean age of 20.3 ± 9 years and with a male (53%) predominance. Focal epilepsy were more
common (53%), among whom secondary generalized epilepsy was the most frequent diagnosis (67%) followed by
complex partial seizure (21%). Among those with Idiopathic Generalized Epilepsy (46%), generalized tonic clonic
seizure was encountered in 74% and absence seizure was observed in 13%. The number of patients on monother-
apy and dual AED therapy were 67% and 24% respectively and polytherapy (i.e. >3 AEDs) was used only in 9%.
CBZ (67%) was the most frequently prescribed AED, followed by VPA (43%), PHB (17%), and PHT (8%). CBZ was
prescribed in 37% patients as monotherapy followed by VPA in 21% and PHB in 8% patients. Newer generation
drugs eg lemotrigine and topiramate were used only as add on therapy in combination with CBZ and VPA in only
2% patients. The treatment retention rates over the follow up period for the AEDs in monotherapy varied between
86 and 91% and were highest for CBZ, followed by VPA. Most of the combination regimens had a treatment
retention rate of 100%. The effectiveness of AED in terms of reduction of seizure frequency was highest for PHT
(100%) and PHB (98%) followed by CBZ (96%) and VPA (95%). PHB and PHT were the cheapest of all AEDs (42 I$
and 56 I$/ year respectively). The costs of VPA and CBZ were two times and LTG and TOP were six to eight times
higher. Adverse drug reaction (ADR) were observed among 140 (24.5%) of those with monotherapy. PHT (64%) was
the most common drug to cause ADR, CBZ was at the bottom of the list to cause adverse effect (11.6%). VPA and
PHB caused weight gain commonly. Adjustment of drug dose or withdrawal due to ADRs was necessary in 39%
with PHT and 26% with PHB.
Conclusion: Though PHT and PHB are cheapest and efficacious among all, CBZ and VPA are less costly, effective
and well tolerated drug for seizure control in context of Bangladesh.
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Epilepsy is a common and chronic neurologic disorder
worldwide. The risk of having epilepsy at some point in
average life span of any individual varies between 2%-5%
[1]. Some hospital and community based studies from
South East Asian countries (SEAR) have reported the in-
cidence of epilepsy from 2–10 per thousand population
[1]. WHO estimates that there are at least 1.5-2.0 mil-
lion people with epilepsy in Bangladesh [1]. The inci-
dence and prevalence of epilepsy being higher in poor
areas (49 to 225 per 100,000 people per year) [2], poses
a huge social and economic burden to the poor. About
half of the total epilepsy population lives in Asia [3].
Though most of the AEDs are cheap, the volume of pre-
scription and duration of treatment often makes the ex-
penditure high enough for the poor. As the definition
implies, epilepsy is a disorder of uncertainty and unpre-
dictability. A seizure event can occur anytime, anywhere
without warning; causing embarrassment, injury or even
death of the person [4]. This may have a disastrous ef-
fect on employment and independence [5]. About 50%
of the patients become seizure free with the first drug
tried and can lead a normal life [6]. Seizure can be con-
trolled with monotherapy in majority of them [7].
This usually requires careful and rigid adherence to
drug regimens, which involve taking tablets regularly,
two or three times each day for many years, sometimes
for a lifetime. Physicians often judge the effectiveness of
treatment by gross clinical response. There are wide var-
iations in each person’s response to treatment, and the
plasma concentration of AEDs provides little informa-
tion about a person’s likelihood of reduction of seizures
or side-effects. The available data on effectiveness of
drugs are mostly from the western studies [8]. But the
drug response and effectiveness may vary depending on
the genetic, environmental, pharmacodynamic and phar-
macokinetic interaction in different racial groups. More-
over, the cost of AEDs often poses a treatment gap in
management of epilepsy, especially in least developed
country like Bangladesh. So our aim was to find out the
effectiveness and side effect profile of AEDs used in epi-




This is a retrospective chart review, carried out from
hospital records in weekly Epilepsy outdoor clinic of
Department of Neurology, DMCH from October 1998
to February 2013. During this period a total of 3284 pa-
tients with seizure disorder attended the epilepsy clinic
of DMCH. Among them, 854 epilepsy patients met our
inclusion criteria from hospital database. Patients aged
5 yrs and above with seizure disorders who were infollow up for at least two years from the last AED added
and had a complete set of desired information (patients
identity, age, sex, occupation, comprehensive clinical his-
tory of seizure including duration, frequency, types etc.,
any associated disorders, examination findings, investi-
gation reports and the drug usage profile with any ad-
verse event) in record files were included in the study.
A questionnaire (Summery of information is listed in
next section) was used to take data regarding demo-
graphics (age and gender), type and epileptic seizures,
age of onset of seizures, frequency of seizure at onset
(number of seizure per six months) and at the end of
follow up, duration of disease and therapy, duration of
follow-up at DMCH, clinical or biochemical evidence of
any adverse drug reaction. The epilepsy clinic used sim-
ple 1981 international league against epilepsy (ILAE)
classification system to label the seizure events in record
file (Commission on Classification and Terminology of
the International League Against Epilepsy, 1981). So we
grouped seizure events simply as partial (complex par-
tial, simple partial, secondary generalized), generalized
(generalized tonic-clonic, absence, myoclonic, clonic,
tonic, atonic) and unclassified. Those not following any
particular type was labeled unclassified.
List of collected information




II. Variables related to Seizure:
1. Age of onset of seizure
2. Duration of disease
3. Seizure type
4. Classification of epilepsy
5. Duration of Previous Therapy
6. Duration of Follow Up
7. Seizure frequency at first visit
8. Seizure frequency at the end of follow up
9. Percentage reduction of seizure frequency
III. Drug related information:
1. Number of AED used
2. AED dose at initial visit and at every follow up
3. AED dose range
4. Change in seizure frequency
IV. Adverse drug reaction:
1. Change in blood picture
2. Skin reaction
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We had to exclude a large number of patients who did
not return to follow up or were in follow up for less than
two years. Though we excluded all the patients diag-
nosed as pseudo-seizure and those with structural brain
lesion (tumor, heamatoma, cyst, tuberculoma or any
other space occupying lesion), epilepsy patients with co-
morbid psychiatric illness like anxiety, depression were
included in this study. We also excluded all the patients
with incomplete hospital record. There was no differ-
ence in demography, seizure types or drug utilization
pattern between the included or excluded patients.
During the record keeping every patient was examined
initially by post graduate trainees and later evaluated
and treated by consultant neurologists. Diagnosis was
made on clinical ground. EEG and other investigations
were done only in required cases. After proper recording
EEG were analyzed and reported by two Neurologist of
Dept. of Neurology of DMCH. EEG showing focal epi-
leptiform activity was labeled as LRE (Localization Re-
lated Epilepsy) and generalized epileptic activity was
labeled as GE (Generalized Epilepsy).
Operational definitions
Epilepsy: Tendency to have recurrent seizure.
Low Cost AED: Any AED costing 3 taka or less per
tablet in local market (1 US $ is equivalent to approxi-
mately 82 taka).
Effectiveness: It is measured as treatment retention
rate at the end of follow up and percentage in reduction
of seizure frequency from the time of drug initiation.
Treatment retention rate: It is the percentage of pa-
tients who were maintained on the initial anti epileptic
drug at the end of follow up period.
Seizure free at the end: It was evaluated as percent-
age of patients who are seizure free at the end of follow
up period.
Reduction in seizure frequency: The frequency of
seizure was calculated as the number of seizure events
per six month before initial visit and at every follow up
visit. The difference of seizure frequency was calculated
by subtracting number of events per six month from the
previous value. In epilepsy clinic patients are asked to
maintain a diary of seizure events with date, time and
duration which are kept written in patient record form.
Antiepileptic drug with effectiveness and tolerability
profile
Drug related data included the AED regimen (name, num-
ber, dose range) at initial visit and at the end of follow up
along with any adverse drug reaction. The effectiveness of
antiepileptic was measured by treatment retention rate
(the percentage of patients which were maintained on the
same AED therapy since the time from their first visit orstart of therapy at DMCH (de novo patients) and the
number of patients who were seizure free on a particular
AED regimen at the end of the follow-up period (at least
2 years after the last drug added). Seizure frequency was
recorded as number of seizure events per six months both
at the time of first visit and the subsequent follow up.
Treatments were provided by experienced neurologists
(Professor of neurology to Assistant professor) in the
clinic. They also recorded any adverse drug reaction either
reported by the patient or found through routine examin-
ation and investigation during follow up. Tolerability was
measured by extracting data from the record files on the
known adverse reactions (any cytopenia in blood, skin re-
actions, mouth, gastro-intestinal, liver, central nervous sys-
tem problems, change in body weight etc.) of these drugs.
At least 5% gain of weight during follow up was consid-
ered to be related to AED usage.
Cost of antiepileptic drugs
The cost of AEDs were calculated as average price of
standard dose per tablet (e.g. CBZ 200 mg tab) in local
market from the average of at least 5 top pharmaceutical
companies. We collected the price of standard doses
form of tablets from the local market. All the drug price
of five commonly prescribed pharmaceutical companies
were summated and subdivided by five to get the arith-
metic mean of the individual drugs. We multiplied the
unit price with average maintenance dose of the drug.
The rough average annual cost was also calculated. The
price of the drug is paid by the patients themselves ex-
cept for the PHB and PHT which are provided free of
cost by the government and available at medical college
hospitals and also at local government hospitals.
Though PHB is under tight regulation in many coun-
tries, it is still readily available in Bangladesh. To adjust
the price in regional context the unit price (cost per
tablet) was also calculated in International Dollars (I$).
An International Dollar has the same purchasing power
as the U.S. Dollar in United States. The conversion
from local currency to (I$) is made by using the purchas-
ing power parity (PPP) exchange rates. A PPP exchange
rate is the number of units of a country’s currency re-
quired to buy the same amount of goods and services in
the domestic market as the U.S Dollar would by in United
States. The PPP exchange rate in 2005 for Bangladesh
Taka is 13.03 [9].
Statistical analysis
Data were recorded and descriptive statistical analysis
was done with SPSS version 16.0 system. χ2-test was
used in the comparison of quantitative data where re-
quired. The significance of the results as determined at
95.0% confidence interval (CI) and a value of P < 0.05
was consider to be statistically significant.
Table 2 Classification of epileptic seizure (n = 854)
Parameter n %






Partial epilepsy 452 53
SPS 50 11
CPS 97 22
Secondary GS 305 67
Unclassified 29 3
GTCS = Generalized Tonic Clonic Seizure, SPS = Simple Partial seizure, CPS =
Complex Partial Seizure.
Table 3 Treatment of epilepsy (n = 854)
Treatment n %
No of AED used
Monotherapy 572 67
Two drugs 205 24
Three drugs or more 77 9
AED Prescribed in clinic
CBZ 318 37
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The study protocol was approved by the ethical review
committee of Dhaka Medical College.
Results
Out of 3179 patients who visited the epilepsy clinic at
DMCH, 854 were selected through the eligibility criteria.
The majority of the patients attending outdoor clinic
were >11-30 years age group (55.2%) with a mean age of
20.3 ± 9 years. There was a male (53%) predominance
(Table 1). Considering the types of epileptic seizure, par-
tial/focal seizure were more common (53%), among
whom secondary generalized seizure was the most fre-
quent diagnosis (67% of partial seizure) followed by
complex partial seizure (22%). Out of those with gener-
alized epilepsy (44%), generalized tonic clonic seizure
was encountered in 74% and absence seizure was ob-
served in 12%. Despite the entire endeavor, about 3% of
seizure patients remained unclassified (Table 2).
At the end of the follow-up period, the total number
of AEDs prescribed were 1144, corresponding to an
average of 1.34 AEDs per patient. The number of pa-
tients on monotherapy and dual AED therapy were 572
(67%) and 205 (24%) respectively. Polytherapy (i.e. >3
AEDs) was used in only 77 patients (9%). Irrespective of
the AED prescription pattern (whether on monotherapy
or combination therapy), CBZ (67%) was the most fre-
quently prescribed AED, followed by VPA (43%), PHB
(17%), and PHT (8%). About 37% of the patients re-
ceived CBZ as monotherapy followed by VPA in 21%
and PHB in 8% patients. Among the combination ther-
apy, CBZ and VPA was most commonly used (14.5%) as
dual therapy and CBZ, VPA and PHT (4%) as polyther-
apy. Newer generation drugs eg lemotrigine and topira-
mate was used only as add on therapy in combination
with CBZ and VPA (Table 3). Irrespective of the seizure
type, the treatment retention rates over the last 2 years
for the AEDs in monotherapy varied between 86 andTable 1 Demographic profile of the patients (n = 854)
Parameter n %
Age
<10 yrs 167 19.5
11-20 yrs 198 23.2
21-30 yrs 273 32
31-40 yrs 120 14
41-50 yrs 43 5
51-60 yrs 34 4
>60 yrs 19 2.3
Sex
Male 453 53
Female 401 4791% and were highest for CBZ, followed by VPA. Most
of the combination regimens had a treatment retention
rate of 100%. Effectiveness of the AEDs was also mea-
sured as the number of patients being seizure free over
this last 2-year period. The effectiveness in terms of re-
duction of seizure frequency was highest for PHT
(100%) and PHB (98%) followed by CBZ (96%) and
VPA (95%) (Table 4). Treatment retention rate and




CBZ + VPA 115 13.5
CBZ + PHB 34 4
CBZ + PHT 26 3
VPA + PHB 21 2.5
CBZ + VPA + PHT 34 4
CBZ + PHB + PHT 26 3
CBZ + VPA + TOP 8 1
CBZ + VPA + LTG 8 1
PHB = Phenobarbitone, CBZ = Carbamazepine, VPA = Sodium Valproate, PHT =
Phenytoine, TOP = Topiramate, LTG = Lemotrigine.
Table 4 Efficacy of AED regimen (n = 854)
AED regimen Retention rate
At the end of F/U
(%/ number of patients)
P value Seizure free
At the end of F/U
(%/ Number of patients)
P value
CBZ 91 (287/318) 96 (275/287)
VPA 86 (154/179) 95 (146/154)
PHB 22 (15/ 68) 98 (14/15)
PHT 29 (5/ 17) 100 (5/5)
CBZ + VPA 100 (115/115) 96 (110/115)
CBZ + PHB 88 (30/34) <0.001 90 (27/30) <0.001
CBZ + PHT 65 (17/26) 76 (13/17)
VPA + PHB 77 (16/21) 88 (14/16)
CBZ + VPA + PHT 100 (34/34) 88 (30/34)
CBZ + PHB + PHT 92 (24/26) 75 (18/24)
CBZ + VPA + TOP 100 (8/8) 88 (7/8)
CBZ + VPA + LTG 100 (8/8) 88 (7/8)
PHB = Phenobarbitone, CBZ = Carbamazepine, VPA = Sodium Valproate, PHT = Phenytoine, TOP = Topiramate, LTG = Lemotrigine.
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for both variables).
The average costs of mean daily maintenance dose of
AEDs were compared with regard to local currency and
International Dollars (I$). PHB and PHT were the
cheapest of all AEDs available in Bangladesh. The annual
cost of PHB 60 mg dose and PHT 300 mg dose were
about 1096 taka and 2190 taka (84 I$ and 168 I$) re-
spectively. The cost of VPA and CBZ was slightly higher
(196 I$ and 254 I$). But LTG and TOP were very much
expensive (672 I$ and 560 I$) (Table 5). Out of 572 pa-
tients on monotherapy, adverse drug reaction (ADR)
were observed among 140 (24.5%) of them. The detail of
category and type of reaction is given in Table 6. PHT
(64%) was the most common drug to cause ADR, espe-
cially in the form of gum hypertrophy and CNS manifes-
tations. Though CBZ caused some serious reactions like
anaemia, skin rash etc., it was the least common drug to
cause ADR (11.6%). About 25.7% patients with VPA and
23.5% patient with PHB experienced ADR. Both of them
caused weight gain commonly. Adjustment of drug dose
or withdrawal due to ADRs was necessitated in 39% with
PHT, 26% with PHB, 9% of patients with VPA and 8% of
patients with CBZ in this study.
Discussion
Epilepsy imposes a huge economic burden on health
care system, especially in resource poor countries where
the incidence may be as high as 190 per 100,000 people
[10]. The Global Campaign Against Epilepsy was estab-
lished by the International League Against Epilepsy
(ILAE), the International Bureau for Epilepsy (IBE), and
WHO in order to tackle the management issues related
to epilepsy [11]. WHO suggests that medical disordersthat require a low technological approach should be
managed at the primary health-care level. There are
studies from both developed and developing countries
on economic analysis of epilepsy which have shown sig-
nificant economic burden of epilepsy [12–14]. These evi-
dences from research in rich countries may or may not
accurately predict similar outcome in poor countries. In
this context of low priority and high treatment gap of
epilepsy care in developing countries, the study was
done to establish the low cost and effective first line
AED for Bangladesh.
Most of our index population was younger age group
(55.2% belonging to 11-30 years age group). The report co-
incides with Mannan et al. [15] (16-31 years) in Bangladesh.
Mac et al. [16] showed a bimodal age distribution of epi-
lepsy patients in developed country with a first peak in
childhood and another one in old age. Except for Shanghai
in China, most of the Asian countries have younger pa-
tients with epilepsy. The probable reason for the missing
peak in the older age group in many Asian countries is due
to the fact that most of the population are younger com-
pared to number of old people [16,17]. Similar to reports
from other Asian countries, there was slightly male pre-
dominance [18].
In contrast to the reports from most of the Asian
countries, where the IGE ranges from 50-69% and partial
seizure from 31-50%, our index population predomin-
antly had partial epilepsy (53%) [19–22]. Often it is quite
difficult to compare the results of these studies due to
lack in application of standardized classification system
in epilepsy research in Asia and lack of imaging and
electroencephalographic studies, which probably had
lead to predominance of IGE in most of the studies. We
had the advantage of tertiary care facilities in this
Table 5 Cost of AEDs








CBZ 400 200 (3.5) 2556 196.12
VPA 600 200 (3) 3285 252.06
PHB 60 30 (1.5) 1096 84.10
PHT 300 100 (2) 2190 168.06
TOP 50 25 (10) 7300 560.24
LTG 100 50 (12) 8760 672.28
1Local currency.
2International dollar is calculated by purchasing power parity (PPP).
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LRE/focal epilepsy in our study. In a similar hospital
based study in Srilanka, Senanayake classified 59.7% pa-
tients as secondary generalized seizure. Several series of
studies from Liberia, Mumbai, Madras, Brazil reported
the frequency between 40-50% [23,24].
Monotherapy has been the gold standard of epilepsy
treatment for last 20 years. Most (67%) of the patients in
our study was successfully maintained on monotherapy.
Various first generation AEDs like PHB, PHT, CBZ, VPA
and clonazepum are widely used as monotherapy in
most of the Asian countries [25–30]. A series of trials by
Reynolds and Shorvon [31–33] also showed similar ef-
fectiveness with monotherapy. Not surprisingly CBZ was
the most common (67%) AED prescribed as LRE was
encountered more frequently. The choice of AED as
monotherapy varied between studies, where VPA may be
first choice as broad spectrum AED or both used equally
[34–36]. Conventionally, most of the neurologists prefer
VPA for IGE and CBZ for LRE. The Cochrane review
[37] provides very little support for this, where VPA
showed marginally favorable outcome for IGE. In the
Cochrane review of five head-to-head studies in partial
epilepsy, CBZ was just superior to VPA. In our study
PHT and PHB had the highest level of effectiveness in
terms of reduction of seizure frequency, but had veryTable 6 Adverse drug reactions (ADR) with AED monotherapy
Type of reaction C
67 (1
Blood Aneamia, pancytopenia 1
Skin Rash, urticaria, photosensitivity, SJS 1
Mouth Gum hypertrophy/hyperplasia, ulcer
GIT Nausea, vomiting 2
Liver Hepatitis 1
CNS Drowsiness, ataxia, vertigo
Body weight 1low retention rate than CBZ and VPA due to higher rate of
adverse events in the former drugs. The difference was also
statistically significant across the AED used in terms of
both the treatment retention rate (p value <0.001) and seiz-
ure freedom rate (p value <0.001) at the end of follow up.
In contrast to this a published clinical trial from Caucasian
and Japanese study showed only 30% retention rate at a
median follow up period [38].
PHB was recommended by WHO as the treatment of
choice for partial and tonic clonic seizures in resource
restricted countries [39]. The strategy had been ques-
tioned because of low tolerability with PHB than other
antiepileptic drugs [40]. Concerns apply particularly to
children, who are especially vulnerable to cognitive and
behavioural adverse effects of PHB [41]. But in a study
by Banu [42] and colleagues in Bangladesh found no sig-
nificant difference in behavioral problems such as rest-
lessness and hyperactivity between PHB and CBZ (7% v
11%). Though more efficacious in seizure reduction, the
treatment retention rate at the end of follow up period
on PHB and PHT were very low compared to CBZ and
VPA. The discontinuation of former drugs is probably
due to their ADR profile. For causality assessment of
ADR we only have considered those on monotherapy.
Henceforth, we could not evaluate the side effect profile
of LTG and TOP, as they were used only as add onAED
N (%)
BZ VPA PHB PHT
1.6%) 46 (25.7%) 16 (23.5%) 11 (64%)
5 1 0 0
1 0 0 0
0 0 0 7
3 4 7 0
4 3 1 0
1 0 0 2
7 31 10 9
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A category, that is, they are predictable, dose dependent,
and explained by the known pharmacological properties
of individual agents [43]. The overall rate of adverse
events in our study was higher than that of Mathur et al.
[44] (4.67%), but similar to Roopa et al. [45] (10.2%) who
reported from a tertiary care hospital like ours. Similar
to other studies the ADR was maximum with PHT,
followed by VPA and PHB [46]. Most of the side effects
correspond well with the known adverse effect profile of
PHT [47]. Coinciding our report, Carpay et al. [48] also
observed more weight gain with the VPA and PHT, com-
pared o CBZ. VPA has traditionally been associated with
a greater incidence of weight gain than that of other
AEDs [49]. The percentage of patients requiring changes
in their dose regimen due to ADR was comparable for
both VPA and CBZ.
This type of cost effectiveness analysis helps in setting
the priority for allocation of public health research. Be-
yond efficacy and cost, availability of AED is also a crit-
ical factor for successful implementation of wide range
of health care delivery though out the whole nation. The
WHO CHOICE [50] work program was under taken in
different developing countries to find out effective strat-
egy to combat epilepsy. Such process involved different
key parameters like effective treatment coverage, drug
price and unit cost of health care service delivery. PHB
and PHT are the cheapest AED found in Bangladesh.
But the cost of newer generation AEDs like TOP and
LTG are six to eight times higher. This is a vital eco-
nomic factor when the cost of long term treatment is
borne mostly by patients themselves.
The major limitations in the study include the retro-
spective nature and the variability in treatment of epi-
lepsy patients by different neurologists at the epilepsy
clinic. We tried to reduce the observer biasness by fol-
lowing the ILAE classification system and common
treatment guideline followed by the responsible consul-
tants. We had to exclude a large number of patients who
either did not return to follow up or did not complete
two years of follow up. The poor follow up may be due
to the fact that, the epilepsy clinic of DMCH which is
the highest center of referral for patients with epilepsy,
encounters patients from all the corners of Bangladesh.
Most of them are poor. It often becomes quite difficult
for them to come to Dhaka for follow up. Though we
have considered the treatment retention rate and num-
ber of patient being seizure free at the end of follow up
as the measure of effectiveness, the severity of individual
seizure events were not considered for analysis. We also
could not measure the drug adherence based on medica-
tion collection or follow up. Because in Bangladesh there
is no database system for recording the medication dis-
pensed or collected by the patients. Moreover, the studyfrom hospital records may not completely represent the
scenario in the community.
Conclusion
The use of older AEDs in primary health care settings is
expected to be a very cost effective approach due to
lower price and established effectiveness profile. The
four conventional old generation drugs (PHB, PHT, CBZ
and VPA) recommended by WHO is still effective in our
population. Though PHT and PHB are least expensive
drugs, their use is limited by the higher rate of adverse
event. Henceforth, CBZ and VPA may be effective, less
costly and well tolerated drugs in our settings where re-
sources are limited. So the routine use of these four low
cost AED may avert the burden of epilepsy treatment in
developing and under developed countries.
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